Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.
作者信息
Ragni M V, Yabes J G, Fogarty P F, Josephson N C, Kessler C M, Neff A T, Raffini L, Brummel-Ziedins K, Moore C G
机构信息
Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.
出版信息
Haemophilia. 2017 Jan;23(1):e43-e46. doi: 10.1111/hae.13131. Epub 2016 Dec 11.
Abstract
摘要
相似文献
1
Pilot randomized, non-inferiority, cross-over trial of once-weekly vs. three times-weekly recombinant factor VIII prophylaxis in adults with severe haemophilia A.
Haemophilia. 2017 Jan;23(1):e43-e46. doi: 10.1111/hae.13131. Epub 2016 Dec 11.
2
Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.
Haemophilia. 2017 May;23(3):408-416. doi: 10.1111/hae.13160. Epub 2017 Feb 24.
3
Pilot study of once-a-day prophylaxis for youth and young adults with severe haemophilia A.
Haemophilia. 2016 Sep;22(5):e401-5. doi: 10.1111/hae.13058. Epub 2016 Aug 1.
4
The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey.
Haemophilia. 2008 Sep;14(5):923-30. doi: 10.1111/j.1365-2516.2008.01810.x. Epub 2008 Jul 14.
5
Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.
Expert Rev Hematol. 2011 Oct;4(5):495-507. doi: 10.1586/ehm.11.52.
6
Long-term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A.
Haemophilia. 2016 Jan;22(1):72-80. doi: 10.1111/hae.12766. Epub 2015 Jul 27.
7
Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Haemophilia. 2016 May;22(3):e177-83. doi: 10.1111/hae.12869. Epub 2016 Mar 14.
8
Experience of tailoring prophylaxis using factor VIII pharmacokinetic parameters estimated with myPKFiT in patients with severe haemophilia A without inhibitors.
Haemophilia. 2017 Jan;23(1):e50-e54. doi: 10.1111/hae.13141.
9
Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres.
Haemophilia. 2012 Jan;18(1):63-8. doi: 10.1111/j.1365-2516.2011.02554.x. Epub 2011 May 4.
10
Optimizing factor prophylaxis for the haemophilia population: where do we stand?
Haemophilia. 2004 Oct;10 Suppl 4:97-104. doi: 10.1111/j.1365-2516.2004.00998.x.
引用本文的文献
1
Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B.
Cochrane Database Syst Rev. 2021 Aug 18;8(8):CD014201. doi: 10.1002/14651858.CD014201.
2
Comparative evaluation of the safety and efficacy of recombinant FVIII in severe hemophilia A patients.
J Pharmacopuncture. 2018 Jun;21(2):76-81. doi: 10.3831/KPI.2018.21.009. Epub 2018 Jun 30.
3
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.
Res Pract Thromb Haemost. 2018 May 20;2(3):535-548. doi: 10.1002/rth2.12106. eCollection 2018 Jul.
本文引用的文献
1
A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management.
J Thromb Haemost. 2012 Mar;10(3):359-67. doi: 10.1111/j.1538-7836.2011.04611.x.
2
Recommendations for planning pilot studies in clinical and translational research.
Clin Transl Sci. 2011 Oct;4(5):332-7. doi: 10.1111/j.1752-8062.2011.00347.x.
3
Rationale for a randomized controlled trial comparing two prophylaxis regimens in adults with severe hemophilia A: the Hemophilia Adult Prophylaxis Trial.
Expert Rev Hematol. 2011 Oct;4(5):495-507. doi: 10.1586/ehm.11.52.
4
Challenges of rare disease research: limited patients and competing priorities.
Haemophilia. 2012 May;18(3):e192-4. doi: 10.1111/j.1365-2516.2011.02646.x. Epub 2011 Sep 13.
5
The longitudinal effect of body adiposity on joint mobility in young males with Haemophilia A.
Haemophilia. 2011 Mar;17(2):196-203. doi: 10.1111/j.1365-2516.2010.02400.x.
6
The paradoxical problem with multiple-IRB review.
N Engl J Med. 2010 Oct 21;363(17):1591-3. doi: 10.1056/NEJMp1005101. Epub 2010 Oct 13.
7
Thrombin generation and bleeding in haemophilia A.
Haemophilia. 2009 Sep;15(5):1118-25. doi: 10.1111/j.1365-2516.2009.01994.x. Epub 2009 Jun 26.
8
Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices.
Haemophilia. 2009 Sep;15(5):1014-21. doi: 10.1111/j.1365-2516.2009.02036.x. Epub 2009 Jun 1.
9
Effects of secondary prophylaxis started in adolescent and adult haemophiliacs.
Haemophilia. 2008 Sep;14(5):945-51. doi: 10.1111/j.1365-2516.2008.01791.x. Epub 2008 Jun 5.
10
Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data.
Haemophilia. 2007 Sep;13(5):473-9. doi: 10.1111/j.1365-2516.2007.01478.x.
Zotero 插件